


Fungal Immunology Group

Giorgos Chamilos, MD
hamilos@imbb.forth.gr

**Institute of Molecular Biology and
Biotechnology (IMBB), Foundation of
Research and Technology (FORTH), Greece**




Invasive mold infections (IMI): **emerging** and **underestimated** human diseases



- ***Aspergillus*** and **Mucorales** fungi
- **400,000** pts/year, > **50%** mortality, **\$2 billion** annual cost (US), **evolving** epidemiology
- Patients with mold infection display complex **immunometabolic defects**

The pathobiology of invasive mold infections is incompletely understood

The evolving epidemiology of IMIs




Our research approach

Using **molds as model pathogens**:


- ❑ Study **physiological immunity in phagocytes**
- ❑ Delineate mechanisms of **disease pathogenesis**
- ❑ **Translational directions**:
 - i. Identify **biomarkers** of phagocyte dysfunction
 - ii. Explore targeted **host-directed therapies**

Our experimental strategy



Novel Regulators of Phagocyte Immunity

LC3-associated phagocytosis (LAP), a specialized autophagy pathway, orchestrates antifungal immunity



Kyrmizi..., and Chamilos *J Immunol* **2013**






Akoumianaki..., and Chamilos *Cell Host Microbe* **2016**

Kyrmizi..., and Chamilos *Nat Microbiol* **2018**


Andrianaki..., and Chamilos *Nat Commun* **2018**

Akoumianaki..., and Chamilos *Cell Host Microbe* **2021**

Uncoupling of cytokine signaling from LAP drives immunoparalysis in sepsis



Uncoupling of cytokine signaling from LAP drives immunoparalysis in sepsis




Clinical predictors of COVID-19 Associated Pulmonary Aspergillosis (CAPA)			
Variable	Multivariable Hazard Ratio	95%CI	P- value
Age per year	1.04	1.02-1.06	<0.001
Any invasive respiratory support	3.40	1.84-6.25	<0.001
Tocilizumab	2.45	1.41-4.25	<0.001

Future collaborative efforts

Organize a **National Fungal Pneumonia Network**

- **5 University Hospitals, 3 Clinical Cohorts**
- **Open access Biobank** (multi-omics, functional assays, organoids)
- Disease mechanisms, biomarkers, prognostic models





European Research Council



Collaborating Labs

School of Medicine, University of Crete

Elias Drakos, MD, PhD

Zoi Veneti, PhD

George Samonis, MD

Katerina Vaporidi, MD, PhD

BRFAA, Athens

Vagelis Andreakos, PhD

Kalliopi Thanopoulou, PhD

Institute of Microbiology, HKI, Jena, Germany

Axel A. Brakhage, PhD

University of Crete, Greece

Jean-Paul Latge, PhD

INSERM-U1149, CNRS-ERL8252, Paris, France

Jamel El-Benna, PhD

Fungal Pathogenesis Unit, NIH, USA

Michalis Lionakis, MD

University of Cincinnati, USA

Julio A Landero, PhD

George Deepe, MD

Radboud University, Netherlands

Frank L van de Veerdonk, MD

Mihai Netea, MD

University of Groningen, Netherlands

Vinod Kumar, PhD

School of Health Sciences, University of Minho,
Portugal

Agostinho Carvalho, PhD

Cristina Cunha, PhD

3B's Research Group, University of Minho, Portugal

Nuno M. Neves, PhD

Helena Ferreira, PhD

The MDACC, University of Houston, Houston,

Dimitrios P Kontoyiannis, MD

University of Maryland, Baltimore

Vincent Bruno, PhD

Harbor-UCLA Medical Center

Ashraf S Ibrahim, PhD

Thank you!